DrugPatentWatch Database Preview
Genus Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for GENUS, and what generic alternatives to GENUS drugs are available?
GENUS has ten approved drugs.
There are fourteen US patents protecting GENUS drugs.
There are eighty patent family members on GENUS drugs in twenty-eight countries and twenty-four supplementary protection certificates in thirteen countries.
Summary for Genus
| International Patents: | 80 |
| US Patents: | 14 |
| Tradenames: | 9 |
| Ingredients: | 9 |
| NDAs: | 10 |
Drugs and US Patents for Genus
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genus Lifesciences | YOSPRALA | aspirin; omeprazole | TABLET, DELAYED RELEASE;ORAL | 205103-002 | Sep 14, 2016 | RX | Yes | Yes | 9,364,439 | Start Trial | Y | Start Trial | |||
| Genus Lifesciences | LEVOLET | levothyroxine sodium | TABLET;ORAL | 021137-005 | Jun 6, 2003 | DISCN | No | No | Start Trial | Start Trial | |||||
| Genus | HYDROCODONE BITARTRATE AND ACETAMINOPHEN | acetaminophen; hydrocodone bitartrate | SOLUTION;ORAL | 040894-001 | Jul 19, 2011 | AA | RX | No | No | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for GENUS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 81 mg/40 mg | ➤ Subscribe | 2016-10-14 |
International Patents for Genus Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Israel | 247034 | Start Trial |
| South Korea | 20140077945 | Start Trial |
| Japan | 2012502015 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Genus Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1411900 | C300481 | Netherlands | Start Trial | PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17901/0263-001 20101105 |
| 1411900 | 132012902015795 | Italy | Start Trial | PRODUCT NAME: NAPROSSENE E ESOMEPRAZOLO SALE DI MAGNESIO TRIIDRATO(VIMOVO); AUTHORISATION NUMBER(S) AND DATE(S): PL 17901/0263-0001, 20101105;DA 40611016/M A 40611129/M, 20110808 |
| 0253310 | SPC/GB95/010 | United Kingdom | Start Trial | PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
